Optimizing anti-thymocyte globulin dosing in allogeneic hematopoietic stem cell transplantation: individualized approaches and clinical implications.

Front Immunol · 2025 · PMC12370499 · PMID 40861446

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

showed a trendP = 0.061so close (0.05 < p ≤ 0.1)

While no significant difference in NRM and recurrence were observed between two groups, optimal AUC group showed a trend toward better 2-year OS (75.7% vs. 57.8%, P = 0.061) ( 19 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.